β-Lactam antibiotics, such as penicillins, cephalosporins and carbapenems, are the largest family of antimicrobial agents, and have been widely used in this clinical practice.1 However, the emergence and the increased frequency of antimicrobial resistance has become a serious health problem. For this reason, the development of new antimicrobial drugs becomes a worldwide priority. Doripenem (formerly known as S-4661) is a new synthetic 1-β-methyl carbapenem antibiotic developed by Shionogi (Osaka, Japan). Doripenem is a new synthetic 1-β-methyl carbapenem antibiotic with a broad-spectrum activity against clinically pathogens including Enterobacteriaceae, non-fermenting gram-negative, anaerobes, and many gram-positive both in vivo and in vitro, including some carbapenem resistant.2, 3, 4, 5 Recently, doripenem was indicated in the United States and Europe for the treatment of intraabdominal and complicated urinary tract infections including pyelonephritis, and approved in the Europe for patients with nosocomial pneumonia including ventilator-associated pneumonia.4

The aim of this study is to evaluate the in vitro activity of doripenem against enterococci and E. coli isolates from wild animals, pigs, pets, poultry and humans in Portugal.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD